Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Magnetic Resonance Cholangio Pancreatography | Research article

Elevated hemoglobin A1c is associated with the presence of pancreatic cysts in a high-risk pancreatic surveillance program

Authors: Ariel Bar-Mashiah, Anne Aronson, Monica Naparst, Christopher J. DiMaio, Aimee L. Lucas

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

Emerging evidence demonstrates that surveillance of individuals at high-risk (HRIs) of developing pancreatic adenocarcinoma allows for identification and treatment of resectable tumors with improved survival. Population-based data suggest that hyperglycemia may be present up to three years before the development of pancreatic cancer. We investigated whether elevated hemoglobin A1c (HbA1c) is associated with the development of pancreatic cysts in a pancreatic surveillance program.

Methods

We performed a retrospective study of HRIs who underwent pancreatic surveillance at a single institution between May 2013 and March 2019, according to published criteria. We collected demographic information, clinical data including HbA1c, and imaging results. We compared data using univariable and multivariable analyses. Our primary outcome was the presence of pancreatic cysts on initial surveillance in patients with elevated HbA1c.

Results

Ninety-eight patients underwent surveillance imaging via EUS or MRCP and seventy-four patients met inclusion criteria. Thirty patients were found to have cysts on initial imaging. Older age (p < 0.01) and HbA1c in the prediabetic range or higher (p = 0.01) were associated with the presence of cysts or solid lesions on univariable analysis. After controlling for confounders, age (aOR 9.08, 95% CI 2.29–36.10), and HbA1c > 5.7% (aOR 5.82, 95% CI 1.50–22.54) remained associated with presence of cysts and solid lesions in HRIs. In patients with cysts or solid lesions there was a strong association between increased age and elevated HbA1c (p < 0.01).

Conclusion

HRIs with elevated HbA1c were more likely to have pancreatic cysts compared to individuals with lower HbA1c on initial imaging in a pancreatic surveillance program. These findings may help tailor the surveillance protocols for those at increased risk of developing pancreatic adenocarcinoma.
Literature
1.
go back to reference Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.CrossRef Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.CrossRef
2.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef
3.
go back to reference Al-Sukhni W, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet. 2008;124(3):271–8.CrossRef Al-Sukhni W, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet. 2008;124(3):271–8.CrossRef
4.
go back to reference Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the international Cancer of the pancreas screening (CAPS) consortium. Gut. 2020;69(1):7–17. Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the international Cancer of the pancreas screening (CAPS) consortium. Gut. 2020;69(1):7–17.
5.
go back to reference Jones S, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217.CrossRef Jones S, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217.CrossRef
6.
go back to reference Kastrinos F, et al. Risk of pancreatic cancer in families with lynch syndrome. JAMA. 2009;302(16):1790–5.CrossRef Kastrinos F, et al. Risk of pancreatic cancer in families with lynch syndrome. JAMA. 2009;302(16):1790–5.CrossRef
7.
go back to reference Rebours V, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103(1):111–9.CrossRef Rebours V, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103(1):111–9.CrossRef
8.
go back to reference Roberts NJ, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–6.CrossRef Roberts NJ, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–6.CrossRef
9.
go back to reference van Lier MGF, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258–64 author reply 1265.CrossRef van Lier MGF, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258–64 author reply 1265.CrossRef
10.
go back to reference Zhen DB, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17(7):569–77.CrossRef Zhen DB, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17(7):569–77.CrossRef
11.
go back to reference Canto MI, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology. 2018;155(3):740–51 e2.CrossRef Canto MI, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology. 2018;155(3):740–51 e2.CrossRef
12.
go back to reference Canto MI, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804 quiz e14–5.CrossRef Canto MI, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804 quiz e14–5.CrossRef
13.
go back to reference Abe T, et al. Deleterious Germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. J Clin Oncol. 2019;37(13):1070–80.CrossRef Abe T, et al. Deleterious Germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. J Clin Oncol. 2019;37(13):1070–80.CrossRef
14.
go back to reference Pannala R, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88–95.CrossRef Pannala R, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88–95.CrossRef
15.
go back to reference Pannala R, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981–7.CrossRef Pannala R, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981–7.CrossRef
16.
go back to reference Sharma A, et al. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155(2):490–500 e2.CrossRef Sharma A, et al. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155(2):490–500 e2.CrossRef
17.
go back to reference Canto MI, et al. International Cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.CrossRef Canto MI, et al. International Cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.CrossRef
18.
go back to reference Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62 quiz 263.CrossRef Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62 quiz 263.CrossRef
19.
go back to reference Tanaka M, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.CrossRef Tanaka M, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.CrossRef
20.
go back to reference Tada M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4(10):1265–70.CrossRef Tada M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4(10):1265–70.CrossRef
21.
go back to reference Pani LN, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham offspring study and the National Health and nutrition examination survey 2001-2004. Diabetes Care. 2008;31(10):1991–6.CrossRef Pani LN, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham offspring study and the National Health and nutrition examination survey 2001-2004. Diabetes Care. 2008;31(10):1991–6.CrossRef
22.
go back to reference Bosetti C, et al. Cigarette smoking and pancreatic cancer: an analysis from the international pancreatic Cancer case-control consortium (Panc4). Ann Oncol. 2012;23(7):1880–8.CrossRef Bosetti C, et al. Cigarette smoking and pancreatic cancer: an analysis from the international pancreatic Cancer case-control consortium (Panc4). Ann Oncol. 2012;23(7):1880–8.CrossRef
23.
go back to reference Paiella S, et al. Results of first-round of surveillance in individuals at high-risk of pancreatic Cancer from the AISP (Italian Association for the Study of the pancreas) registry. Am J Gastroenterol. 2019;114(4):665–70.CrossRef Paiella S, et al. Results of first-round of surveillance in individuals at high-risk of pancreatic Cancer from the AISP (Italian Association for the Study of the pancreas) registry. Am J Gastroenterol. 2019;114(4):665–70.CrossRef
24.
go back to reference Hart PA, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1(3):226–37.CrossRef Hart PA, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1(3):226–37.CrossRef
25.
go back to reference Chari ST, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504–11.CrossRef Chari ST, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504–11.CrossRef
26.
go back to reference Garg SK, et al. Glycemic Profile of Subjects with Familial Pancreatic Cancer: Mayo Clinic Experience from 2000-2018. Gastroenterology. 2019;156(6):S–38. Garg SK, et al. Glycemic Profile of Subjects with Familial Pancreatic Cancer: Mayo Clinic Experience from 2000-2018. Gastroenterology. 2019;156(6):S–38.
27.
go back to reference Boursi B, et al. A clinical prediction model to assess risk for pancreatic Cancer among patients with new-onset diabetes. Gastroenterology. 2017;152(4):840–50 e3.CrossRef Boursi B, et al. A clinical prediction model to assess risk for pancreatic Cancer among patients with new-onset diabetes. Gastroenterology. 2017;152(4):840–50 e3.CrossRef
28.
go back to reference Hart PA, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas. 2011;40(5):768–72.CrossRef Hart PA, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas. 2011;40(5):768–72.CrossRef
29.
go back to reference Arslan AA, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the pancreatic Cancer cohort consortium (PanScan). Arch Intern Med. 2010;170(9):791–802.CrossRef Arslan AA, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the pancreatic Cancer cohort consortium (PanScan). Arch Intern Med. 2010;170(9):791–802.CrossRef
30.
go back to reference Genkinger JM, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer. 2011;129(7):1708–17.CrossRef Genkinger JM, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer. 2011;129(7):1708–17.CrossRef
31.
go back to reference Jiao L, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control. 2010;21(8):1305–14.CrossRef Jiao L, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control. 2010;21(8):1305–14.CrossRef
32.
go back to reference Amin S, Boffetta P, Lucas AL. The role of common pharmaceutical agents on the prevention and treatment of pancreatic Cancer. Gut Liver. 2016;10(5):665–71.CrossRef Amin S, Boffetta P, Lucas AL. The role of common pharmaceutical agents on the prevention and treatment of pancreatic Cancer. Gut Liver. 2016;10(5):665–71.CrossRef
33.
go back to reference Amin S, et al. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol. 2016;111(9):1350–7.CrossRef Amin S, et al. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol. 2016;111(9):1350–7.CrossRef
Metadata
Title
Elevated hemoglobin A1c is associated with the presence of pancreatic cysts in a high-risk pancreatic surveillance program
Authors
Ariel Bar-Mashiah
Anne Aronson
Monica Naparst
Christopher J. DiMaio
Aimee L. Lucas
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01308-w

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.